Research programme: factor Xa inhibitors - MolecumeticsAlternative Names: Factor Xa inhibitors research programme - Molecumetics
Latest Information Update: 04 Sep 2000
At a glance
- Originator Molecumetics
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Blood coagulation disorders
Most Recent Events
- 04 Sep 2000 Discontinued-Preclinical for Coagulation disorders in USA (PO)
- 19 Nov 1997 New profile
- 19 Nov 1997 Preclinical development for Coagulation disorders in USA (PO)